# Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI

> **NCT06787430** · PHASE4 · NOT_YET_RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 170 (estimated)

## Conditions studied

- STEMI - ST-segment Elevation Myocardial Infarction

## Interventions

- **DRUG:** nicorandil
- **DRUG:** Saline (NaCl 0,9 %) (placebo)

## Key facts

- **NCT ID:** NCT06787430
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06787430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06787430, "Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06787430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*